"Our goal is to increase the likelihood of success within the clinic to make better drugs and vaccines and get them into the marketplace and to the patients faster," says William Warren, PhD, Head of the VaxDesign Campus, Sanofi Pasteur. "This in vitro human immune system enables us to measure vaccine efficacy earlier and more predictably."
The MIMIC® platform represents a truly disruptive technology for the study of vaccines and other biologics with immunomodulatory potential, as it provides a novel in vitro model for evaluating human immune responses against candidate drugs, adjuvants, and vaccines. It has shown game-changing advantages over conventional approaches to safety and efficacy testing.
Provided by Mary Ann Liebert, Inc.
This Phys.org Science News Wire page contains a press release issued by an organization mentioned above and is provided to you “as is” with little or no review from Phys.Org staff.